

Kholoud Porter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6810366/publications.pdf>

Version: 2024-02-01

140
papers

7,582
citations

50244

46
h-index

58549

82
g-index

144
all docs

144
docs citations

144
times ranked

8095
citing authors

#	ARTICLE	IF	CITATIONS
1	A highly virulent variant of HIV-1 circulating in the Netherlands. <i>Science</i> , 2022, 375, 540-545.	6.0	39
2	Phylogenetic estimation of the viral fitness landscape of HIV-1 set-point viral load. <i>Virus Evolution</i> , 2022, 8, veac022.	2.2	1
3	Evaluating medical conferences: the emerging need for a quality metric. <i>Scientometrics</i> , 2020, 122, 759-764.	1.6	8
4	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. <i>Clinical Infectious Diseases</i> , 2020, 71, 2905-2916.	2.9	16
5	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. <i>Clinical Infectious Diseases</i> , 2019, 69, 2218-2227.	2.9	52
6	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , 2019, 188, 1569-1577.	1.6	75
7	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. <i>Statistics in Medicine</i> , 2019, 38, 2428-2446.	0.8	13
8	Reorienting health systems to care for people with HIV beyond viral suppression. <i>Lancet HIV</i> , 2019, 6, e869-e877.	2.1	57
9	Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 314-320.	0.9	6
10	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. <i>Aids</i> , 2019, 33, 327-337.	1.0	5
11	Virological remission after antiretroviral therapy interruption in female African HIV seroconverters. <i>Aids</i> , 2019, 33, 185-197.	1.0	11
12	Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 102-109.	0.9	2
13	Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort. <i>Aids</i> , 2018, 32, 161-169.	1.0	19
14	Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. <i>Aids</i> , 2018, 32, 327-335.	1.0	13
15	Easy and accurate reconstruction of whole HIV genomes from short-read sequence data with shiver. <i>Virus Evolution</i> , 2018, 4, vey007.	2.2	64
16	Substantial Heterogeneity in Progress Toward Reaching the 90-90-90 HIV Target in the WHO European Region. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 28-37.	0.9	29
17	CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA. <i>Frontiers in Immunology</i> , 2018, 9, 928.	2.2	50
18	A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study. <i>Lancet HIV</i> , 2018, 5, e301-e308.	2.1	34

#	ARTICLE	IF	CITATIONS
19	From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa. <i>Lancet HIV</i> , 2017, 4, e223-e230.	2.1	59
20	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV</i> , 2017, 4, e251-e259.	2.1	10
21	Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990-2014. <i>Journal of Hepatology</i> , 2017, 67, 255-262.	1.8	56
22	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. <i>Clinical Infectious Diseases</i> , 2017, 64, 1644-1656.	2.9	46
23	A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England. <i>BMJ Open</i> , 2017, 7, e016494.	0.8	12
24	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. <i>Journal of Infectious Diseases</i> , 2017, 216, 1063-1069.	1.9	20
25	Towards standardized definitions for monitoring the continuum of HIV care in Europe. <i>Aids</i> , 2017, 31, 2053-2058.	1.0	19
26	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 311-318.	0.9	12
27	Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 126-133.	0.9	32
28	Men and the young are key to reaching the first 90. <i>Lancet HIV</i> , 2017, 4, e479-e480.	2.1	4
29	Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection. <i>Aids</i> , 2017, 31, 477-484.	1.0	51
30	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2869-2878.	1.3	17
31	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2862-2868.	1.3	5
32	A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations. <i>Clinical Infectious Diseases</i> , 2017, 65, 1127-1135.	2.9	10
33	Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. <i>PLoS Biology</i> , 2017, 15, e2001855.	2.6	38
34	The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. <i>Aids</i> , 2016, 30, 879-888.	1.0	9
35	Constructing the cascade of HIV care. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 102-108.	1.5	65
36	Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 69-73.	0.9	38

#	ARTICLE	IF	CITATIONS
37	Beyond viral suppression of HIV – the new quality of life frontier. <i>BMC Medicine</i> , 2016, 14, 94.	2.3	279
38	Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 100-108.	0.9	15
39	Relating HIV testing patterns in Poland to risky and protective behaviour. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 423-431.	0.6	9
40	HIV Incidence Estimates Using the Limiting Antigen Avidity EIA Assay at Testing Sites in Kiev City, Ukraine: 2013-2014. <i>PLoS ONE</i> , 2016, 11, e0157179.	1.1	10
41	The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels. <i>Aids</i> , 2015, 29, 1355-1361.	1.0	16
42	The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK. <i>PLoS ONE</i> , 2015, 10, e0132772.	1.1	2
43	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. <i>Aids</i> , 2015, 29, 2323-2333.	1.0	21
44	HIV Testing and Diagnosis Rates in Kiev, Ukraine: April 2013 - March 2014. <i>PLoS ONE</i> , 2015, 10, e0137062.	1.1	14
45	A systematic review of definitions of extreme phenotypes of HIV control and progression. <i>Aids</i> , 2014, 28, 149-162.	1.0	83
46	HIV-1-specific CD4 + responses in primary HIV-1 infection predict disease progression. <i>Aids</i> , 2014, 28, 699-708.	1.0	27
47	Development and future directions for the Joint United Nations Programme on HIV/AIDS estimates. <i>Aids</i> , 2014, 28, S411-S414.	1.0	9
48	Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. <i>Aids</i> , 2014, 28, 1193-1202.	1.0	453
49	Using incidence assays within the context of the recent infections testing algorithm. <i>Aids</i> , 2014, 28, 2167.	1.0	1
50	Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 15-21.	0.9	16
51	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. <i>Lancet HIV</i> , 2014, 1, e119-e126.	2.1	32
52	Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. <i>Lancet HIV</i> , 2014, 1, e41-e48.	2.1	17
53	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	2.9	140
54	High Percentage of Recent HIV Infection Leading to Onward Transmission in Odessa, Ukraine Associated with Young Adults. <i>AIDS and Behavior</i> , 2014, 18, 411-418.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression. <i>Aids</i> , 2014, 28, 869-874.	1.0	30
56	An Evaluation of HIV Elite Controller Definitions within a Large Seroconverter Cohort Collaboration. <i>PLoS ONE</i> , 2014, 9, e86719.	1.1	80
57	Effect of HCV Infection on Cause-Specific Mortality After HIV Seroconversion, Before and After 1997. <i>Gastroenterology</i> , 2013, 144, 751-760.e2.	0.6	76
58	Short-Course Antiretroviral Therapy in Primary HIV Infection. <i>New England Journal of Medicine</i> , 2013, 368, 207-217.	13.9	194
59	Short-Course Antiretroviral Therapy in Primary HIV Infection. <i>New England Journal of Medicine</i> , 2013, 368, 2036-2037.	13.9	2
60	Risk of tuberculosis following HIV seroconversion in high-income countries. <i>Thorax</i> , 2013, 68, 207-213.	2.7	26
61	Immunovirologic Control 24 Months After Interruption of Antiretroviral Therapy Initiated Close to HIV Seroconversion—Reply. <i>JAMA Internal Medicine</i> , 2013, 173, 475.	2.6	0
62	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. <i>Clinical Infectious Diseases</i> , 2013, 56, 888-897.	2.9	88
63	High Percentage of Recent HIV Infection Among HIV-Positive Individuals Newly Diagnosed at Voluntary Counseling and Testing Sites in Poland. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 805-813.	0.5	18
64	Natural history of HIV-control since seroconversion. <i>Aids</i> , 2013, 27, 2451-2460.	1.0	44
65	Rate of CD4 Decline and HIV-RNA Change Following HIV Seroconversion in Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 441-446.	0.9	48
66	Role of HIV Infection Duration and CD4 Cell Level at Initiation of Combination Anti-Retroviral Therapy on Risk of Failure. <i>PLoS ONE</i> , 2013, 8, e75608.	1.1	8
67	Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy. <i>PLoS ONE</i> , 2013, 8, e78287.	1.1	74
68	Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration. <i>PLoS ONE</i> , 2013, 8, e71174.	1.1	12
69	Symptomatic Illness and Low CD4 Cell Count at HIV Seroconversion as Markers of Severe Primary HIV Infection. <i>PLoS ONE</i> , 2013, 8, e78642.	1.1	9
70	Immunovirologic Control 24 Months After Interruption of Antiretroviral Therapy Initiated Close to HIV Seroconversion. <i>Archives of Internal Medicine</i> , 2012, 172, 1252.	4.3	102
71	Uptake of Combination Antiretroviral Therapy and HIV Disease Progression According to Geographical Origin in Seroconverters in Europe, Canada, and Australia. <i>Clinical Infectious Diseases</i> , 2012, 54, 111-118.	2.9	16
72	Evaluating the systems used to monitor HIV populations accessing therapy and care in low-income and lower-middle-income countries. <i>Aids</i> , 2012, 26, S137-S145.	1.0	0

#	ARTICLE	IF	CITATIONS
73	Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection. <i>Aids</i> , 2012, 26, 887-890.	1.0	19
74	Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience. <i>Clinical Investigation</i> , 2012, 2, 255-264.	0.0	10
75	Molecular epidemiology of recent HIV-1 infections in southern Poland. <i>Journal of Medical Virology</i> , 2012, 84, 1857-1868.	2.5	9
76	Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection. <i>Antiviral Therapy</i> , 2012, 17, 1039-1048.	0.6	3
77	Differences in HIV Natural History among African and Non-African Seroconverters in Europe and Seroconverters in Sub-Saharan Africa. <i>PLoS ONE</i> , 2012, 7, e32369.	1.1	30
78	Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection. <i>PLoS ONE</i> , 2012, 7, e43754.	1.1	60
79	Mean Corpuscular Volume as a Marker for Adherence to Zidovudine-Containing Therapy in HIV-Infected Adults. <i>Open AIDS Journal</i> , 2012, 6, 45-52.	0.1	4
80	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 363-371.	4.6	345
81	Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. <i>BMJ: British Medical Journal</i> , 2011, 343, d6016-d6016.	2.4	282
82	The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. <i>Aids</i> , 2011, 25, 1083-1091.	1.0	120
83	Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naïve individuals. <i>Aids</i> , 2011, 25, 1041-1049.	1.0	14
84	Setting Up a Standardized Peripheral Blood Mononuclear Cells Processing Laboratory to Support Multi-center HIV/AIDS Vaccine and Intervention Trials. <i>Laboratory Medicine</i> , 2011, 42, 711-718.	0.8	3
85	Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds ≤ 200, ≤ 350, and ≤ 500 Cells/mm ³ : Assessment of Need Following Changes in Treatment Guidelines. <i>Clinical Infectious Diseases</i> , 2011, 53, 817-825.	2.9	180
86	Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. <i>Aids</i> , 2011, 25, 1395-1403.	1.0	38
87	Antiretroviral treatment of primary HIV infection to reduce onward transmission. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 283-290.	1.5	32
88	CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. <i>Aids</i> , 2010, 24, 2697-2704.	1.0	29
89	The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 633-639.	0.9	25
90	2010 Guidelines for Antiretroviral Treatment of HIV From the International AIDS Society's USA Panel. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1897.	3.8	9

#	ARTICLE	IF	CITATIONS
91	Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV Seroconversion. <i>Journal of the National Cancer Institute</i> , 2010, 102, 784-792.	3.0	111
92	Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients Initiating Antiretroviral Therapyâ€”The CASCADE Collaboration: A Collaboration of 23 Cohort Studies. <i>PLoS Medicine</i> , 2010, 7, e1000239.	3.9	54
93	An appraisal of indicators used to monitor the treated population in antiretroviral programmes in low-income countries. <i>Aids</i> , 2010, 24, 2603-2607.	1.0	8
94	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per $\hat{1}\frac{1}{4}$ L in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , 2010, 376, 340-345.	6.3	82
95	Late diagnosis in the HAART era: proposed common definitions and associations with mortality. <i>Aids</i> , 2010, 24, 723-727.	1.0	72
96	Phylogenetic Reconstruction of Transmission Events from Individuals with Acute HIV Infection: Toward Moreâ€”Rigorous Epidemiological Definitions. <i>Journal of Infectious Diseases</i> , 2009, 199, 427-431.	1.9	36
97	CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. <i>Haematologica</i> , 2009, 94, 875-880.	1.7	81
98	Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations? A New Definition Derived From a Large Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 391-396.	0.9	4
99	Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. <i>Aids</i> , 2009, 23, 1743-1753.	1.0	200
100	Changes in the incidence and predictors of human immunodeficiency virusâ€”associated dementia in the era of highly active antiretroviral therapy. <i>Annals of Neurology</i> , 2008, 63, 213-221.	2.8	167
101	Current CD4 Cell Count and the Shortâ€”Term Risk of AIDS and Death before the Availability of Effective Antiretroviral Therapy in HIVâ€”Infected Children and Adults. <i>Journal of Infectious Diseases</i> , 2008, 197, 398-404.	1.9	87
102	Changes in Outcome of Persons Initiating Highly Active Antiretroviral Therapy at a CD4 Count Less Than 50 Cells/mm ³ . <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 202-205.	0.9	15
103	Gender Differences in HIV Progression to AIDS and Death in Industrialized Countries: Slower Disease Progression Following HIV Seroconversion in Women. <i>American Journal of Epidemiology</i> , 2008, 168, 532-540.	1.6	82
104	Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 51.	3.8	404
105	The effect of antiretroviral treatment of different durations in primary HIV infection. <i>Aids</i> , 2008, 22, 2441-2450.	1.0	26
106	Late Presenters in an HIV Surveillance System in Italy During the Period 1992-2006. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 282-286.	0.9	74
107	Primary HIV infection: to treat or not to treat?. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 4-10.	1.3	29
108	Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?. <i>Aids</i> , 2008, 22, 349-356.	1.0	18

#	ARTICLE	IF	CITATIONS
109	Survival following HIV infection of a cohort followed up from seroconversion in the UK. <i>Aids</i> , 2008, 22, 89-95.	1.0	41
110	Response to combination antiretroviral therapy: variation by age. <i>Aids</i> , 2008, 22, 1463-1473.	1.0	188
111	Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. <i>Aids</i> , 2008, 22, 1943-1950.	1.0	16
112	Rates and Determinants of Virologic and Immunological Response to HAART Resumption After Treatment Interruption in HIV-1 Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 49, 492-498.	0.9	11
113	Clinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cART). <i>Open AIDS Journal</i> , 2008, 2, 3-9.	0.1	13
114	Temporal Trends in Postseroconversion CD4 Cell Count and HIV Load: The Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. <i>Journal of Infectious Diseases</i> , 2007, 195, 525-534.	1.9	44
115	Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. <i>Aids</i> , 2007, 21, 1283-1291.	1.0	26
116	Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naïve individuals with high CD4 cell count. <i>Aids</i> , 2007, 21, 1717-1721.	1.0	75
117	Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study. <i>Antiviral Therapy</i> , 2007, 12, 189-93.	0.6	8
118	Effect of Transient Antiretroviral Treatment during acute HIV Infection: Comparison of the Quest Trial Results with CASCADE Natural History Study. <i>Antiviral Therapy</i> , 2007, 12, 189-194.	0.6	24
119	Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. <i>Aids</i> , 2006, 20, 741-749.	1.0	193
120	The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. <i>Aids</i> , 2006, 20, 21-28.	1.0	92
121	Highly Active Antiretroviral Therapy Interruption. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 42, 554-561.	0.9	62
122	Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance Algorithms. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 40, 505-511.	0.9	69
123	Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. <i>Aids</i> , 2005, 19, 487-494.	1.0	120
124	The Rate of Viral Rebound after Attainment of an HIV Load <50 Copies/mL According to Specific Antiretroviral Drugs in Use: Results from a Multicenter Cohort Study. <i>Journal of Infectious Diseases</i> , 2005, 192, 1387-1397.	1.9	35
125	Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. <i>Aids</i> , 2005, 19, 2001-2007.	1.0	85
126	Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 1033-1041.	2.4	21

#	ARTICLE	IF	CITATIONS
127	Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. <i>Aids</i> , 2004, 18, 1697-1705.	1.0	56
128	Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion. <i>Aids</i> , 2004, 18, 673-681.	1.0	35
129	Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters. <i>Aids</i> , 2004, 18, 1471-1473.	1.0	30
130	The empirical evidence for the impact of HIV on adult mortality in the developing world. <i>Aids</i> , 2004, 18, S9-S17.	1.0	51
131	Determinants of survival following HIV-1 seroconversion after the introduction of HAART. <i>Lancet, The</i> , 2003, 362, 1267-1274.	6.3	336
132	Short-Term CD4 Cell Response After Highly Active Antiretroviral Therapy Initiated at Different Times From Seroconversion in 1500 Seroconverters. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 32, 303-310.	0.9	22
133	Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. <i>International Journal of Epidemiology</i> , 2002, 31, 951-958.	0.9	64
134	Detection of drug resistance associated mutations in HIV primary infection within the UK. <i>Aids</i> , 2000, 14, 906.	1.0	32
135	The practical significance of potential biases in estimates of the AIDS incubation period distribution _in the UK Register of HIV Seroconverters. <i>Aids</i> , 1999, 13, 1943-1951.	1.0	33
136	Evaluating the effect of year of seroconversion on HIV progression in cohort studies. <i>Aids</i> , 1998, 12, 1353-1360.	1.0	2
137	AIDS defining diseases in the UK: the impact of PCP prophylaxis and twelve years of change. <i>International Journal of STD and AIDS</i> , 1996, 7, 252-257.	0.5	11
138	Increasing incidence of cryptococcosis in the United Kingdom. <i>Journal of Infection</i> , 1993, 27, 185-191.	1.7	28
139	Routine surveillance data on AIDS and HIV infections in the UK: a description of the data available and their use for short-term planning. <i>Epidemiology and Infection</i> , 1988, 100, 157-169.	1.0	7
140	AIDS AND HEALTH-CARE WORKERS. <i>Lancet, The</i> , 1987, 329, 223-224.	6.3	1